The overall pooled incidence of psoriasis and/or psoriasiform lesions following anti-TNF therapy was 6.0% (5.0-7.0%; <i>I</i><sup>2</sup> = 93.9%), with 6.9% (5.1-8.7%; <i>I</i><sup>2</sup> = 92.4%) for psoriasiform lesions and 4.6% (3.6-5.6%; <i>I</i><sup>2</sup> = 93.9%) for psoriasis. Here, TNF is linked to psoriasis.